A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer

This is a multi-site, open-label, Phase II, randomized, trial to compare the efficacy of RO7198457 versus watchful waiting in patients with circulating tumor DNA (ctDNA) positive, surgically resected Stage II/III rectal cancer, or Stage II (high risk)/Stage III colon cancer.

Phase 2 trials begin testing efficacy in a larger patient group (100–300). This is often where biotech binary events occur — positive Phase 2 data can significantly advance a company's pipeline narrative, while failures can be terminal for a program.

Enrollment is complete. The trial is in its follow-up or data collection phase — a readout may occur on or near the primary completion date.

BioNTech SE (BNTX) is the sponsoring company for this trial. BiotechSign currently grades this company C (53/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.